Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Original vs generic sugammadex for reversal of postoperative residual neuromuscular blockade in children with obstructive sleep apnea
ChiCTR2400086021Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Jun 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Time for the recovery of TOFR to 0.9. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2400086021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086021.